Triple therapy for relapsed CLL after prior treatments
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests three drugs—roginolisib, venetoclax, and rituximab—for people with CLL that has come back or not responded after at least two prior treatments, including a BTK inhibitor. The goal is to see if this combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have CLL that has come back or not responded to treatment and now needs therapy again.
- You must have received at least two prior treatments for CLL, including a BTK inhibitor.
- You must be willing to have two bone marrow biopsies (one before and one during treatment).
- You must be 18 years or older.
- You must have adequate organ function, such as enough platelets, normal kidney and liver function.
- You cannot have had venetoclax or a PI3K inhibitor in the last 6 months, or any CLL treatment within 5 half-lives before starting.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (pirtobrutinib, venetoclax, and obinutuzumab) given for a limited time to people whose CLL/SLL has come back after prior treatment. The goal is to see if this combination can control the cancer and possibly allow a treatment-free period.
This trial tests how well venetoclax (a targeted pill for CLL) works in people whose CLL has come back or hasn’t responded. It also closely tracks early changes in the CLL cells to better understand what happens during treatment.
This trial tests a combination of three drugs—nemtabrutinib, venetoclax, and obinutuzumab—for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal is to see if this combination is safe and effective in treating the disease.
This study tests a combination of sonrotoclax plus obinutuzumab or rituximab versus the current standard venetoclax plus rituximab for people whose CLL or SLL has come back or not responded to previous treatment. The goal is to see which approach helps keep the cancer from growing longer.
This Phase 2 study tests pirtobrutinib plus venetoclax plus obinutuzumab in people with untreated chronic lymphocytic leukemia (CLL) or CLL-related Richter transformation (RT). The goal is to see if this “triplet” combination works better and is safe enough to control the disease.
This trial tests a three-drug combination for people who have not yet had treatment for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It aims to improve outcomes with a targeted, mostly oral regimen.
Hear when a new Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.